by rvvadmin | Feb 17, 2021 | 2021
TORONTO, Feb. 17, 2021 – Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce that,...
by rvvadmin | Feb 12, 2021 | 2021
TORONTO, Feb. 12, 2021 – Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE:RVV) (USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce that it...
by rvvadmin | Feb 11, 2021 | 2021
TORONTO, Feb. 11, 2021 – Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to provide a...
by rvvadmin | Feb 9, 2021 | 2021
TORONTO, Feb. 09, 2021 – Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE:RVV) (USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce that,...
by rvvadmin | Feb 9, 2021 | 2021
TORONTO, Feb. 08, 2021 – Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE:RVV) (USA: RVVTF), announces that it has filed a Form 51-102F4 Business Acquisition Report (BAR) pursuant to National Instrument 51-102 Continuous Disclosure Obligations in...
